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Objectives The purpose of this study is to assess the effectiveness of defibrillation testing (DT) in patients undergoing im-
plantable cardioverter-defibrillator (ICD) insertion.
Background Although DT is considered a standard procedure during ICD implantation, its usefulness has not been definitively
proven.
Methods The SAFE-ICD (Safety of Two Strategies of ICD Management at Implantation) study is a prospective observational
study designed to evaluate the outcome of 2 strategies: performing defibrillation testing (DT) versus not per-
forming defibrillation testing (DT) during de novo ICD implants. No deviation from the centers’ current practice
was introduced. In all, 2,120 consecutive patients (836 DT and 1,284 DT) age 18 years were enrolled at
41 Italian centers from April 2008 to May 2009 and followed up for 24 months until June 2011. The primary
endpoint was a composite of severe complications at ICD implant and sudden cardiac death or resuscitation at
2 years.
Results The primary endpoint occurred in 34 patients: 12 intraoperative complications (8 in DT group; 4 in DT group)
and 22 during follow-up (10 in DT group; 12 in DT group). Overall, the estimated yearly incidence (95% confi-
dence interval) was DT 1.15% (0.73 to 1.83) and DT 0.68% (0.42 to 1.12). The difference between the
2 groups was negligible: 0.47% per year (0.15 to 1.10). Mortality from any cause was similar at 2 years (ad-
justed hazard ratio: 0.97 [0.76 to 1.23], p  0.80).
Conclusions In this large cohort of new ICD implants, event rates were similar and extremely low in both groups. These data
indicate a limited clinical relevance for DT testing, thus supporting a strategy of omitting DT during an ICD im-
plant. (Safety of Two Strategies of ICD Management at Implantation [SAFE-ICD]; NCT00661037) (J Am Coll
Cardiol 2012;60:981–7) © 2012 by the American College of Cardiology Foundation
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Defibrillation Testing in ICD Implant September 11, 2012:981–7The standardized requirements
for implantable cardioverter-
defibrillators (ICD) insertion in-
clude defibrillation testing (DT),
consisting of induction and ter-
mination of ventricular fibrilla-
tion (VF). Historically, an effec-
tive DT has been considered part
of standard procedures at inser-
tion to ensure adequate sensing of VF, appropriate connec-
tion of high-voltage electrodes, and the ability of the device
to terminate VF with a shock. Nevertheless, implant tech-
niques and technology have evolved in recent years, and
deviations from this clinical practice are frequent. Reasons
See page 988
may be that ICDs are much more efficient than in the past
due to the improved safety margin of modern ICDs (1–3),
and physicians are concerned more about the risk of severe
complications related to DT (reported to occur in 0.2% to
0.4% of cases in large multicenter surveys) (4,5). In a
national retrospective population survey involving 229 Ital-
ian centers (4), DT was not performed in 30% of the 7,857
de novo ICD implantations. In the Ontario ICD Registry
(6) involving 10 centers, DT was not performed in 35% and
33% of new ICD implants for primary and secondary
prevention, respectively, and in 76% of ICD replacements
(N  2,173). Although DT has never been reliably shown
to improve clinical outcomes, the practice of not performing
DT is arbitrary, and its safety is yet unproven given the lack
of prospective follow-up studies.
The aim of the SAFE-ICD (Safety of Two Strategies of
ICD Management at Implantation) study was to evaluate
the safety, over a follow-up of 2 years, of 2 strategies,
adopted at ICD implant in current clinical practice: induc-
tion, including patients who underwent DT at implant
(DT group), and noninduction, including patients who
did not undergo DT at implant (DT group).
Methods
The SAFE-ICD study was a multicenter, prospective, longi-
tudinal, observational study designed to assess the safety of
DT performed during the implantation procedure, and
DT strategies in consecutive patients undergoing de novo
ICD insertion. No deviation from the centers’ current
practice was introduced by this study protocol. On the basis
of data from the 2005 National Survey (4), 41 Italian centers
were selected according to their common practice of per-
forming or not performing DT at implantation, with the
aim of obtaining balanced populations of DT and DT
patients.
Study population. Consecutive patients, 18 years of age or
ore, with a conventional indication for ICD, regardless of
Abbreviations
and Acronyms
CI  confidence interval
DT  defibrillation testing
ICD  implantable
cardioverter-defibrillator
VF  ventricular fibrillationanufacturer, who were undergoing an initial ICD orcardiac resynchronization therapy device with defibrillation
backup implantation were enrolled. The only exclusion
criterion was a patient’s refusal to provide consent.
Investigators were asked to perform DT or not perform
DT according to their standard practice. Therefore, no
deviation from the centers’ current practice was introduced
by this study protocol. To check for consecutiveness, a
logbook of patients who refused to participate was kept by
each center. Implantation tests were done according to the
center’s practice. Follow-up visits were performed every 6
months until the 24th (1) month.
The primary endpoint consisted of a composite of:
1) severe implant-related complications at ICD insertion
(cardiopulmonary arrest due to VF requiring 3 or more
external shocks for termination or due to electromechanical
dissociation, transient ischemic attack or stroke, cardiogenic
shock, pulmonary edema, embolic events, anoxic coma,
pericardial tamponade, or death); and 2) events at follow-up
(sudden cardiac death, resuscitation after ineffective docu-
mented appropriate ICD shocks). Secondary endpoints were
total mortality and survival after a full series of ineffective
appropriate ICD shocks without resuscitation maneuvers.
Definitions. Sudden cardiac death was defined as wit-
nessed unexpected death occurring 1 h from symptoms
onset or unwitnessed during sleep (7,8). Instantaneous
cardiac death was defined as witnessed unexpected death
occurring within 5 min from symptom onset. Resuscitation
after ineffective documented ICD shock was defined as any
intervention of cardiopulmonary resuscitation including ex-
ternal defibrillation shock and after ineffective ICD
therapy. Cardiac death was defined as any death caused
by a primary cardiovascular problem, including sudden
and nonsudden cardiac death. Noncardiac death was de-
fined as any death not caused by a primary cardiovascular
problem. Death from unknown causes was considered
censored data. The timing for the occurrence of the event
was the date of death. Survival after ineffective ventricular
shock without resuscitation maneuvers was defined as an
episode of sustained ventricular arrhythmias in which a full
series of ICD shocks failed to restore normal sinus rhythm,
without intervention of cardiopulmonary resuscitation in-
cluding external defibrillation shock.
The clinical outcomes of the primary and secondary
endpoints were adjudicated by a Clinical Events Commit-
tee, whose members were unaware of the patients’ study
group.
Sample size and statistical analysis. Limited data are
available on sudden death related to shock failure to treat
VF in ICD patients. Sudden death in patients already
having an ICD are reported to be approximately 1.8% to
2.6% during a follow-up ranging from 1 to 3 years (9–11).
We assumed a 0.5% incidence of primary endpoint events at
ICD implant (4) and a further 2% at the 2-year follow-up in
the DT population, for an overall incidence of events of
2.5% at 2 years. We aimed at an estimated incidence with a
desired precision of 5%. Thus, on the basis of the expected
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September 11, 2012:981–7 Defibrillation Testing in ICD Implantincidence of events at the end of the study of 2.5%, 784
patients allow a 2-sided 97.5% confidence interval to extend
1.3% from the observed incidence (i.e., confidence interval:
1.2% to 3.8%). Similarly, no intraoperative events were
expected for the DT population, whereas a 2.5% inci-
dence of the primary endpoint was expected at the end of the
follow-up, thus leading to the same sample of 784 patients as
above, with a 2-sided 97.5% confidence interval extending
1.3% from the observed incidence (i.e., confidence interval:
1.2% to 3.8%). Therefore, enrollment continued until at least
784 DT and DT patients had been enrolled.
Continuous data are shown as average  SD. Absolute
and relative frequency were used to show categorical data.
Unpaired Student’s t test or Fisher’s exact test was used to
compare continuous and categorical variables. Yearly inci-
dences of the studied outcomes and 95% confidence inter-
vals (95% CI) were calculated. Kaplan-Meier survival esti-
mates for all-cause mortality were plotted, and a Cox model
was fitted, while adjusting (through inverse probability
weights) for the propensity score, to compare all-cause
mortality among DT and DT patients. The propensity
score was computed from a logistic model with DT/DT
as the dependent variable and robust standard error ac-
counting for intracenter correlation, and included the base-
line clinical variables listed in Table 1. The corresponding c
tatistic was 0.66. The Stata 12 software (StataCorp, Col-
ege Station, Texas) was used for computation.
esults
f 2,183 consecutive eligible patients in 41 Italian centers,
total of 2,120 (97%) patients were enrolled from April
008 to May 2009 and followed up prospectively for 24
1) months; 95% of them either completed the follow-up
r died before the 24-month visit. The study ended in June
011. The frequency of DT varied considerably among differ-
nt centers, ranging from 0% to 100% of all ICD implants per
enter (median 39%; interquartile range: 0% to 79%). Overall,
36 (39%) patients had DT performed during the ICD
nsertion procedure and 1,284 (61%) did not. Their character-
stics are listed in Table 1. In particular, among DT patients,
he mean effective shock energy tested during implant was
3 5 J. Safety margin data were available for 695 patients in
he DT group: a safety margin 10 J was present in 648
93%) patients and10 J in 47 (7%). One single induction was
erformed in 720 patients (86%), 2 inductions in 100 (12%),
nd3 in 16 (2%). An external shock was needed in 30 (3.6%)
atients because of ineffective ICD shock at its maximum
nergy; 4 of these latter had cardiopulmonary arrest requiring 3
r more external shocks for termination, and therefore were
ounted as primary endpoint (see following text). In 8 patients,
he defibrillator was unable to convert VF at any attempt
uring insertion.
rimary endpoint. The primary combined endpoint oc-
urred in 18 DT patients and in 16 DT patients (Fig. 1,
ables 2 and 3). Overall, the estimated yearly incidence t95% CI) was DT 1.15% (0.73 to 1.83) and DT 0.68%
0.42 to 1.12) (Fig. 2). The difference between the 2 groups
as negligible: 0.47% per year (0.15 to 1.10). The slightly
igher event rate in DT patients was mainly due to their
igher intraoperative complication rate (Table 2). After
eighting for baseline clinical variables by the propensity score,
Baseline Characteristics of Patients,According to Defibrillation Tes ng GroupsTable 1 B seline Characteristics of Patients,According to Defibrillation Testing Groups
Characteristics
DT
(n  836)
DT
(n  1,284) p Value
Age, yrs 66 12 67 11 0.05
Male 684 (82%) 1,016 (79%) 0.13
Cardiac condition at procedure
Ischemic cardiopathy 467 (56%) 726 (57%) 0.79
Dilated cardiomyopathy 247 (30%) 404 (31%) 0.65
Others 122 (15%) 154 (12%) 0.56
History of congestive heart failure 400 (48%) 752 (59%) 0.001
NYHA functional classification
I 163 (19%) 157 (12%) 0.001
II 411 (49%) 530 (41%)
III 248 (30%) 567 (44%)
IV 12 (1%) 28 (2%)
Echocardiographic ejection fraction, % 32.1 11.6 31.0 10.4 0.02
Heart rate at enrollment, beats/min 70 12 71 14 0.02
Systolic blood pressure at enrollment,
mm Hg
124 17 123 17 0.28
Coexisting conditions
Previous myocardial infarction 431 (52%) 676 (53%) 0.042
Previous CABG and/or PCI 376 (45%) 526 (41%) 0.07
History of atrial fibrillation 221 (27%) 417 (32%) 0.007
Diabetes mellitus 192 (23%) 360 (28%) 0.01
Hypertension 365 (44%) 744 (58%) 0.001
Previous TIA/stroke 44 (5%) 69 (5%) 1.00
Renal insufficiency 182 (22%) 314 (24%) 0.09
Pharmacological therapy
ACE/ARB inhibitors 554 (66%) 913 (71%) 0.02
Beta-blockers 546 (65%) 901 (70%) 0.02
Diuretics 579 (69%) 1,002 (78%) 0.001
Nitrates 127 (15%) 177 (14%) 0.37
Calcium-channel blockers 40 (5%) 75 (6%) 0.33
Antialdosterone 199 (24%) 310 (24%) 0.88
Digitalis 81 (10%) 178 (14%) 0.004
Antiarrhythmics 220 (26%) 298 (23%) 0.11
Anticoagulants 194 (23%) 414 (32%) 0.001
Antiplatelet 378 (45%) 527 (41%) 0.06
Statins 303 (36%) 534 (42%) 0.01
Potassium supplements 51 (6%) 99 (8%) 0.17
ICD indications
Primary prevention 575 (69%) 900 (70%) 0.08
Secondary prevention 254 (30%) 364 (28%) 0.08
Unknown 7 (1%) 20 (2%) —
CRT devices 291 (35%) 595 (46%) 0.001
High-shock energy devices, 40 J* 166 (51%) 273 (51%) 0.98
Values are mean  SD or n (%). *Data available for 325 DT patients (defibrillation testing
performed) and 535 DT patients (defibrillation testing not performed).
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker; CABG  coronary
artery bypass graft surgery; CRT  cardiac resynchronization therapy; ICD  implantable cardio-
verter-defibrillator; NYHA  New York Heart Association; PCI  percutaneous coronary interven-
tion; TIA  transient ischemic attack.he estimated difference between groups remained negligible
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Defibrillation Testing in ICD Implant September 11, 2012:981–7(0.60%), with a hazard ratio of 1.90 (95% CI: 0.96 to 3.95, p
0.07) in DT compared with DT patients.
No primary endpoint occurred during the follow-up among
he patients with a safety margin10 J. The primary endpoint
ccurred in 23 of 1,475 (1.6%) patients in primary prevention
nd 11 of 618 (1.8%) patients in secondary prevention.
econdary endpoints. Although fairly balanced, DT pa-
tients had less severe underlying structural heart disease than
DT patients, as evidenced by lower rate of congestive
heart failure, New York Heart Association functional class
III or IV, atrial fibrillation, higher ejection fraction, and less
usage of diuretics and digoxin (Table 1). Mortality from any
cause at 2 years was slightly (not significantly) lower among
the DT patients than among DT patients (Table 2, Fig. 3),
ith a hazard ratio of 0.86 (95% CI: 0.68 to 1.09, p 0.20).
fter weighting for baseline clinical variables by the pro-
ensity score, the hazard ratio was 0.97 (95% CI: 0.76 to
.23, p  0.80).
During the follow-up, appropriate effective shocks oc-
urred in 223 patients, with a similar proportion in DT
nd DT groups (Table 2); they occurred in 11.6% of
atients with standard-energy devices and in 12.3% of
atients with high-energy devices (p  0.36). Appropriate
neffective shocks occurred in 13 patients, with a similar
roportion in DT and DT groups (Table 2); they
ccurred in 0.95% of patients with standard-energy devices
nd in 1.1% of patients with high-energy devices (p 0.96).
mong the patients with appropriate ineffective shocks, 1
T patient and 2 DT patients survived despite a full
eries of ineffective appropriate ICD shocks without resus-
Figure 1 Patient Flow and Main Results
The observed rate at 2-year follow-up of the primary combined endpoint (severe im
and sudden cardiac death at follow-up) and of death from any cause among patienitation maneuvers (secondary study endpoint). oiscussion
n this very large cohort of patients who underwent inser-
ion of a new ICD, both practices of performing or not
erforming DT at implant were safe, with a low, similar rate
f potentially ICD-related events, including severe compli-
ations during implant and sudden cardiac death at follow-
p. Therefore, the clinical relevance of DT testing is
imited, thus supporting the practice of omitting DT at
mplant.
While the rate of acute implant-related complications
as consistent with that expected, the observed sudden
ardiac death rate in the trial (1.2% and 0.9% in DT and
T patients, respectively) was lower than had been
nticipated from prior studies (9–11). The reasons are not
lear, but seem not to be related to a lower severity of the
isease. Indeed, the overall incidence of appropriate shocks
t 1 year was 7.7%, substantially comparable with that
eported in recent multicenter registries and randomized con-
rolled trials. For example, in the SCD-HeFT (Sudden Car-
iac Death in Heart Failure) trial (12), the average annual rate
f appropriate ICD shocks was 5.1%; and in the large
LTITUDE registry (13), which included both ICD and
ardiac resynchronization therapy, the 1-year incidence of
ppropriate shocks was 8%. Alternative explanations may be
hat modern ICDs have a greater safety margin due to lower
efibrillation threshold, higher shock energy, and better
rrhythmia discrimination, making ICD therapy more reliable
han in the past, and to the higher percentage of primary
revention indication, which was similar in this study to that
elated complications at implantable cardioverter-defibrillator [ICD] insertion
o had undergone defibrillation testing (DT) and among patients who had not.plant-r
ts whbserved in the United States (14), than in the past.
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September 11, 2012:981–7 Defibrillation Testing in ICD ImplantThe SAFE-ICD study shows that, on the one hand,
current ICD recipients are very well protected from sudden
cardiac death irrespective of performing DT or not and, on
the other, that the DT strategy is unlikely to further
decrease sudden cardiac death rate to a value that is clinically
relevant, lower than that of 1% observed in the present study
in DT patients.
Similarly, we did not observe any substantial difference in
all-cause mortality between DT and DT groups. The
slight, nonsignificant lower mortality among DT patients
might be due to these patients having less severe underlying
structural heart disease than DT patients, and it disap-
peared when the 2 groups were analyzed after adjustment of
their baseline clinical characteristics.
The SAFE-ICD is the largest study to date that evalu-
ated clinical hard endpoints and compared the safety of 2
different DT strategies. Until now, only a few small retro-
spective outcome studies (15–17) of selected populations
and largely underpowered to show either superiority or
noninferiority of DT compared to DT have been
published. In the SCD-HeFT trial (18), the first shock
Patient Outcomes,Intraoperatively and During Follow-Up,According o Defibrillatio Testing Groups
Table 2
Patie t O tcom ,
Intraoperatively and During Follow-Up,
According to Defibrillation Testing Groups
Characteristics DT (n  836) DT (n  1,284) p Value
Primary combined outcome 18 (2.1%) 16 (1.2%) 0.11
Implant-related complications 8 (1.0%) 4 (0.3%) 0.10
Cardiopulmonary arrest due to
VF induction requiring
3 external shocks
4 0
TIA or stroke 0 1
Cardiogenic shock 1 0
Pulmonary edema 0 2
Embolic event 1 0
Anoxic coma 0 0
Pericardial tamponade 0 0
Death 2 3
Events during follow-up 10 (1.2%) 12 (0.9%) 0.58
Sudden cardiac death 9 11
Instantaneous, within 5 min 2 3
Resuscitation after ineffective
documented appropriate
ICD shocks
1 1
Total mortality 108 (12.9%) 188 (14.6%) 0.29
Cardiac 62 118
Noncardiac 40 66
Unknown 6 4
Patients with appropriate
ineffective ventricular
shocks during follow-up
7 (0.8%) 6 (0.5%) 0.28
Patients with appropriate
effective ventricular shocks
during 2-year follow-up
85 (10.2%) 138 (10.7%) 0.66
With ICD 64/545 (11.7%) 84/689 (12.2%) 0.86
With CRT-D 21/291 (7.2%) 54/595 (9.1%) 0.37
Values are n (%), n, or n/N (%).
CRT-D  cardiac resynchronization therapy with defibrillation backup; VF  ventricular fibrilla-
tion; other abbreviations as in Table 1.efficacy for ventricular tachyarrhythmias was high regardlessof baseline defibrillation threshold testing results, and base-
line defibrillation threshold testing did not predict long-
term mortality or shock efficacy. Strengths of the SAFE-
ICD study include a large population matching the general
ICD population of Western countries, its prospective de-
sign, a follow-up of 2 years for all patients, the enrollment
of consecutive patients, with a dropout rate of only 3%, the
use of any commercially available ICD device, and no
deviation from the centers’ current practice introduced by
the protocol. All these aspects allow the study to provide a
reliable real-world picture of the practice of modern ICD
utilization.
Study limitations. The present study population had a
slightly lower than expected primary endpoint event rate
because of the low incidence of SCD during follow-up,
which could have been insufficient to show a difference in
Cause of Death in the 25 Patients WhoReached the Primary Endpoint During Follow-UpTable 3 Cause of Death in the 25 Patients WhoReached the Primary Endpoint During Follow-Up
Patient # Group Time Course Description
1 DT Acute Cardiogenic shock
2 DT Acute Cardiogenic shock
3 DT Follow-up Instantaneous SCD with documented
recurrent VF
4 DT Follow-up Instantaneous SCD (5 min from symptoms
onset), cardiac rupture likely
5 DT Follow-up SCD with documented VF,
5 min 60 from symptom onset
6 DT Follow-up SCD, cardiac rupture likely
7 DT Follow-up SCD, acute coronary syndrome likely
8 DT Follow-up SCD, acute coronary syndrome likely
9 DT Follow-up SCD, acute coronary syndrome likely
10 DT Follow-up SCD during sleep
11 DT Follow-up SCD during sleep
12 DT Acute Cardiogenic shock
13 DT Acute Prolonged hypotension, electromechanical
dissociation 15 min after pocket closure,
cardioembolic event likely
14 DT Acute Cardiogenic shock
15 DT Follow-up Instantaneous SCD with documented VF
occurred in coronary care unit (ICD and
external shocks ineffective)
16 DT Follow-up Instantaneous SCD (5 min after symptoms
onset); no detail available
17 DT Follow-up Instantaneous SCD (5 min after symptoms
onset); no detail available
18 DT Follow-up SCD with documented VF,
5 min 60 from symptom onset
19 DT Follow-up SCD with documented VF,
5 min 60 from symptom onset
20 DT Follow-up SCD with documented electromechanical
dissociation after incessant VT,
5 min 60 from symptom onset
21 DT Follow-up SCD with documented electromechanical
dissociation, 5 min 60 from
symptom onset
22 DT Follow-up SCD during sleep
23 DT Follow-up SCD; cardiac pump failure likely
24 DT Follow-up SCD; no detail available
25 DT Follow-up SCD; no detail availableSCD  sudden cardiac death; VT  ventricular tachycardia; other abbreviations as in Tables 1 and 2.
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Defibrillation Testing in ICD Implant September 11, 2012:981–7the clinical effect of DT. Nevertheless, it is noteworthy that
the shock rate was sufficiently high and consistent with
literature data and that the consecutiveness of enrollment in
a large mix of general hospitals represent the general
practice of a Western country.
Admittedly, the absence of randomization and the mod-
est differences in patient characteristics between the DT
and DT groups do not allow us to draw a definite
onclusion. Nevertheless, our findings, with a similar inci-
ence of events with narrow confidence intervals, lead us to
ypothesize that even 2 perfectly matched arms would not
hange the results substantially. A randomized (noninferi-
rity) design would have made the conclusions much
Figure 2 Yearly Incidences of Primary Endpoint
Yearly estimated incidences per 100 patients (with 95% confidence interval) of the
defibrillation testing (DT) and among patients who had not (DT).
Figure 3 All-Cause Mortality
Kaplan-Meier survival estimates for all-cause mortality among patients who had understronger, according to the rules of evidence-based medicine.
However, the ongoing large, prospective, multicenter, ran-
domized, SIMPLE (Shockless Implant Evaluation) study
(19) may confirm and reinforce the results of the SAFE-
ICD study.
Finally, some of the DT performed was possibly inade-
quate to establish an accurate safety margin. However, this
reflects the current clinical practice as well as that of recent
trials. For example, in the SCD-HeFT trial (18), the
adopted safety margin test was not so different from the
strategy adopted in our study. Indeed, in that study, the first
shock was delivered at 20 J; if unsuccessful, the second
attempt was performed with 30 J, and no further VF
ry outcome among patients who had undergone
efibrillation testing (DT [red line]) and patients who had not (DT [blue line]).primagone d
22
2
2
2
2
2
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September 11, 2012:981–7 Defibrillation Testing in ICD Implantinduction was recommended regardless of defibrillation
success of this second induction.
Conclusions
There is ongoing debate as to the need to conduct intraop-
erative DT at the time of ICD insertion (2,9,20–27). Data
coming from real-world experience suggest that despite the
absence of scientific evidence, an increasing number of first
implantation procedures are performed without any induc-
tion test. For example, in 2 large single-center populations,
Russo et al. (2) did not perform any induction test in 4.7%
of implants performed between 1997 and 2003; and Pires
and Johnson (9) did not perform any induction test in 24%
of implants performed between 1996 and 2003. These
initial rates increased to 30% in 2005 (4), to 33% to 35% in
2007 and 2008 (6), and to 61% in 2008 and 2009 in the
present study. The results of the SAFE-ICD trial support
the increasing practice of omitting DT. We expect that the
results of this study may contribute to standardize the “de
novo” ICD implant procedure without DT for the majority
of patients. However, it is possible that DT may continue to
be utilized at implant or delayed after some months (27,28)
in difficult cases such as selected cases of nonstandard lead
position, right-sided ICD pocket, or pediatric implants.
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APPENDIX
For a list of the investigators in the SAFE-ICD study,
please see the online version of this article.
